Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments.
Yong, Shin Jie · Infectious diseases (London, England) · 2021 · DOI
Quick Summary
This review examines what we know about Long COVID, an illness that affects some people after they recover from COVID-19 infection. The main symptoms are extreme tiredness and breathing difficulties that last for months, along with brain fog, pain, and heart problems. Researchers found that Long COVID may be caused by lasting damage to organs like the lungs and brain, combined with ongoing inflammation in the body.
Why It Matters
This review is significant for ME/CFS communities because it identifies Long COVID as potentially sharing overlapping pathophysiology with ME/CFS, POTS, and MCAS—suggesting that treatments developed for these conditions may be relevant to Long COVID patients. Understanding Long COVID mechanisms may also advance knowledge about similar post-viral illnesses, including ME/CFS, which lacks clear etiology.
Observed Findings
Fatigue and dyspnea are the most commonly reported persistent symptoms lasting months after acute COVID-19
Long COVID affects COVID-19 survivors across all severity levels, including asymptomatic infections, mild cases, and non-hospitalized individuals
Additional symptoms frequently reported include cognitive impairment, joint and chest pain, palpitations, myalgia, and cardiac dysfunction
Identified risk factors include female sex, presence of five or more early symptoms, early dyspnea onset, prior psychiatric conditions, and specific blood biomarkers
Multiple proposed pathophysiological mechanisms include viral persistence, immune dysregulation, autoimmunity, and long-term tissue damage
Inferred Conclusions
Long COVID likely results from multiple interacting mechanisms including tissue damage and pathological inflammation rather than a single cause
Risk stratification may be possible using demographic, clinical, and biomarker variables, though more validation is needed
Therapeutic approaches developed for related post-viral and systemic conditions (ME/CFS, POTS, MCAS) warrant investigation in Long COVID populations
Remaining Questions
What specific mechanisms drive viral persistence in Long COVID, and how does this differ from other post-viral illnesses like ME/CFS?
What This Study Does Not Prove
This review does not establish causation for any proposed mechanism or risk factor—it synthesizes existing literature which itself may contain correlational data only. The review acknowledges that precise definitions of Long COVID were lacking at the time, limiting the quality of evidence synthesis. It does not provide robust clinical trial evidence for any specific treatment approach.